Prinivil: Effective Blood Pressure Control for Cardiovascular Health
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.71 | $51.24 (0%) | 🛒 Add to cart |
| 60 | $1.21 | $102.48 $72.34 (29%) | 🛒 Add to cart |
| 90 | $1.05 | $153.71 $94.44 (39%) | 🛒 Add to cart |
| 120 | $0.95 | $204.95 $114.53 (44%) | 🛒 Add to cart |
| 180 | $0.88 | $307.43 $157.73 (49%) | 🛒 Add to cart |
| 270 | $0.83 | $461.14 $223.03 (52%) | 🛒 Add to cart |
| 360 | $0.80
Best per pill | $614.85 $286.33 (53%) | 🛒 Add to cart |
| Product dosage: 2.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 120 | $0.33 | $40.19 (0%) | 🛒 Add to cart |
| 180 | $0.27 | $60.28 $48.22 (20%) | 🛒 Add to cart |
| 270 | $0.22 | $90.42 $59.27 (34%) | 🛒 Add to cart |
| 360 | $0.20
Best per pill | $120.56 $70.33 (42%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.90 | $54.25 (0%) | 🛒 Add to cart |
| 90 | $0.77 | $81.38 $69.32 (15%) | 🛒 Add to cart |
| 120 | $0.71 | $108.50 $85.40 (21%) | 🛒 Add to cart |
| 180 | $0.64 | $162.75 $114.53 (30%) | 🛒 Add to cart |
| 270 | $0.60 | $244.13 $161.75 (34%) | 🛒 Add to cart |
| 360 | $0.58
Best per pill | $325.51 $207.96 (36%) | 🛒 Add to cart |
Synonyms | |||
Prinivil (lisinopril) is an angiotensin-converting enzyme (ACE) inhibitor prescribed for the management of hypertension, heart failure, and post-myocardial infarction care. It works by relaxing blood vessels, allowing blood to flow more smoothly and the heart to pump more efficiently. This medication is a cornerstone in cardiovascular therapy, trusted by clinicians for its proven efficacy and well-established safety profile in appropriate patient populations. Adherence to prescribed treatment can significantly reduce the risk of major cardiovascular events.
Features
- Active ingredient: Lisinopril
- Drug class: Angiotensin-converting enzyme (ACE) inhibitor
- Available in tablet form for oral administration
- Standard dosage strengths: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg
- Typically administered once daily
- Available as a generic medication
Benefits
- Effectively lowers high blood pressure, reducing strain on the heart and arteries
- Improves survival rates after a heart attack when initiated within 24 hours
- Helps manage symptoms of heart failure, increasing exercise tolerance
- Provides renal protective benefits for diabetic patients with proteinuria
- Offers convenient once-daily dosing for improved medication adherence
- Demonstrates a favorable long-term safety profile in clinical use
Common use
Prinivil is primarily indicated for the treatment of hypertension in adults and pediatric patients 6 years and older. It is used either as monotherapy or in combination with other antihypertensive agents. Additionally, it is prescribed as adjunctive therapy in the management of heart failure when standard treatments prove insufficient. For patients who have experienced an acute myocardial infarction, Prinivil is utilized to improve survival when administered within 24 hours of onset of symptoms in hemodynamically stable patients. It is also used in the treatment of diabetic nephropathy, particularly in hypertensive patients with type 2 diabetes mellitus who have microalbuminuria or overt proteinuria.
Dosage and direction
The dosage of Prinivil must be individualized according to patient tolerance and blood pressure response. For hypertension in adults not on diuretic therapy, the initial dose is 10 mg once daily. Maintenance dosage typically ranges from 20-40 mg administered as a single daily dose. For heart failure, the recommended starting dose is 5 mg once daily, which may be increased to a maximum of 40 mg daily. In acute myocardial infarction, dosing should begin with 5 mg within 24 hours of onset of symptoms, followed by 5 mg after 24 hours, 10 mg after 48 hours, and then 10 mg once daily. Pediatric hypertensive patients (6-16 years) should receive an initial dose of 0.07 mg/kg once daily (up to 5 mg). Tablets should be swallowed whole with water and may be taken with or without food.
Precautions
Patients should be monitored for hypotension, especially following the initial dose and during dosage adjustments. Renal function should be assessed prior to initiation and periodically during therapy, particularly in patients with renal impairment, heart failure, or those receiving concomitant diuretics. Serum potassium levels require monitoring, especially in patients with renal impairment, diabetes, or those using potassium-sparing diuretics or potassium supplements. Angioedema may occur at any time during treatment, requiring immediate medical attention. Patients should be advised to avoid dehydration and excessive perspiration. Caucasian patients may have an increased risk of angioedema. Neutropenia/agranulocytosis has been reported with ACE inhibitors, particularly in patients with renal impairment or collagen vascular disease.
Contraindications
Prinivil is contraindicated in patients with a history of angioedema related to previous ACE inhibitor treatment. It should not be used in patients with hereditary or idiopathic angioedema. Concomitant use with aliskiren-containing products is contraindicated in patients with diabetes. The medication is contraindicated in patients who are hypersensitive to any component of this product or to any other ACE inhibitor. Use is contraindicated during the second and third trimesters of pregnancy due to risk of fetal injury and death.
Possible side effect
Common adverse reactions include dizziness (6-12%), headache (5-6%), cough (3-9%), fatigue (3-5%), and diarrhea (3-4%). Other reported side effects include orthostatic effects, rash, impotence, nausea, chest pain, and upper respiratory infection. Serious but less frequent adverse effects may include angioedema (which may involve the face, extremities, lips, tongue, glottis, and/or larynx), hypotension, renal impairment, hyperkalemia, and neutropenia/agranulocytosis. Patients should report any signs of infection (such as sore throat or fever), swelling of face/eyes/lips/tongue, difficulty breathing, or irregular heartbeat promptly to their healthcare provider.
Drug interaction
Concomitant use with diuretics may increase the risk of hypotension. Potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may lead to significant hyperkalemia. Nonsteroidal anti-inflammatory drugs (NSAIDs) may diminish the antihypertensive effect and increase the risk of renal impairment. Dual blockade of the renin-angiotensin system with ARBs, aliskiren, or other ACE inhibitors increases risks of hypotension, hyperkalemia, and renal impairment. Lithium levels may increase with concurrent use. Gold injections (sodium aurothiomalate) have been associated with nitritoid reactions. Antidiabetic agents may require dosage adjustment as Prinivil may enhance their hypoglycemic effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed dose. Consistent daily administration at approximately the same time each day is recommended for optimal blood pressure control. Healthcare providers should educate patients on the importance of adherence to prescribed dosing schedules while providing clear instructions for handling missed doses.
Overdose
Symptoms of overdose may include hypotension, which can be severe, circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety, and cough. Laboratory findings may include hyponatremia and hyperkalemia. Management should focus on supportive care, including volume expansion with normal saline to correct hypotension. Lisinopril may be removed from the body by hemodialysis. Patients should be monitored for electrolyte imbalances and renal function. Symptomatic treatment should be provided as necessary, with particular attention to maintaining adequate renal perfusion.
Storage
Prinivil tablets should be stored at controlled room temperature, 20°-25°C (68°-77°F), with excursions permitted between 15°-30°C (59°-86°F). The medication must be kept in its original container with the lid tightly closed to protect from moisture and light. Tablets should be kept out of reach of children and pets. Unused medication should be properly disposed of according to local regulations once expired or no longer needed. Do not store in bathrooms or other areas with high humidity. Check expiration dates regularly and do not use beyond the printed expiration date.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Prinivil is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Patients should not initiate, discontinue, or change dosage without consulting their physician. The information provided here may not include all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. Healthcare providers should reference the complete prescribing information before administering this medication. Individual patient responses may vary, and treatment decisions should be based on professional medical judgment.
Reviews
Clinical studies have demonstrated Prinivil’s efficacy in reducing blood pressure with once-daily dosing. In the ATLAS study, high-dose lisinopril (32.5-35 mg daily) significantly reduced mortality and hospitalization rates compared to low-dose therapy in heart failure patients. The GISSI-3 trial showed that lisinopril started within 24 hours of myocardial infarction significantly reduced 6-week mortality. Many clinicians report satisfactory blood pressure control in the majority of hypertensive patients, with good long-term tolerability. Some patients note the development of a dry cough, which may necessitate therapy modification. Overall, Prinivil remains a widely prescribed and effective agent in cardiovascular risk management with extensive clinical experience supporting its use.